Predict your next investment

HEALTHCARE | Medical Devices & Equipment / Imaging & Diagnostic Equipment
hemosonics.com

See what CB Insights has to offer

Stage

Loan | Acquired

Total Raised

$26.45M

About HemoSonics

HemoSonics is a medical device company founded to develop and bring to market diagnostics to quantify and characterize the hemostatic potential of whole blood. The company's mission is to save lives and improve the quality of life while reducing costs through the use of our products in all applicable clinical settings. The company's products combine a flexible test device with targeted disposable test chambers to diagnose specific defects of hemostasis and inform appropriate therapy. This approach makes its system easier to operate and interpret than existing products. Potential clinical applications include trauma, cardiovascular procedures, organ transplantation, orthopedic surgery, neurological surgery, and labor and delivery among others.

HemoSonics Headquarter Location

400 Preston Avenue Suite 250

Charlottesville, Virginia, 22903,

United States

434-202-1032

Latest HemoSonics News

HemoSonics Welcomes FDA Support of Viscoelastic Coagulation Analyzers for COVID-19 Patients; Highlights the Benefits of the Quantra® Hemostasis Analyzer

Jan 19, 2021

Download Quantra QPlus System: Quantra Hemostasis Analyzer, QPlus Cartridge. (Photo: Business Wire) January 19, 2021 12:54 PM Eastern Standard Time CHARLOTTESVILLE, Va.--( BUSINESS WIRE )--HemoSonics welcomes the January 14th guidance of the US Food and Drug Administration (FDA) that broadens the use of viscoelastic coagulation analyzers for hospital patient healthcare settings in response to COVID-19. The FDA guidance is intended, for the duration of the COVID-19 public health emergency, to expand the availability of coagulation systems for measurement of whole blood viscoelastic properties to assess hemostasis.1 HemoSonics’s flagship product, the Quantra Hemostasis Analyzer , with its QPlus® cartridge, represents the only viscoelastic coagulation testing (VET) system specifically designed and optimized for rapid and easy operation in point-of-care (POC) settings, such as operating rooms, Emergency Departments, or intensive care units. The Quantra system’s innovative closed-cartridge design requires no open-tube blood manipulation after sample collection. The Quantra system is FDA cleared (de novo) for POC use, which may help to minimize the flow of traffic with sample transporters and/or operators in and out of units designated for the care of COVID-19 patients. “The Quantra System’s intuitive operation and easy-to-interpret Dials display may help streamline what is otherwise a complex process of coagulation testing,” said Bob Roda, CEO of HemoSonics. “The QPlus cartridge provides multiple whole blood coagulation parameters within 15 minutes or less, helping clinicians to make quicker, more informed treatment decisions that support better patient outcomes.” Hypercoagulability, an abnormally increased risk for blood clotting, has been observed in patients with COVID-19.2 Clinical reports have shown that in patients with severe COVID-19 infection, blood clotting abnormalities are likely triggered by the acute inflammatory response.3-7 HemoSonics has advocated for the use of viscoelastic whole blood testing as a tool in the diagnosis and management of COVID-19 patients, consistent with its mission to provide efficient, easy-to-use tools that improve patient care. Since the onset of the global pandemic, HemoSonics has supported several clinical sites in Europe and the US in their quest to understand the potential utility of the Quantra system for the evaluation of coagulation status in COVID-19 patients at the POC setting:7 “The Quantra is the only device on which we can operate safely without needing specialized rooms and a biohazard cabinet.” – Ekaterina Baryshnikova, PhD, IRCCS Policlinico San Donato, Milan, Italy The Quantra system’s innovative ultrasound technology, proprietary closed-cartridge design, unparalleled ease of use, and ease of interpretation make it uniquely suited for use in critical or emergency care settings with COVID-19 patients. For more information on the Quantra QPlus System, email contact@hemosonics.com or visit www.HemoSonics.com . Disclaimer This communication contains information on products which is targeted to a wide range of audiences and could contain product details or information not otherwise accessible or valid in your country. Please refer to the applicable approved instructions for use. About HemoSonics HemoSonics is a medical device company with the primary mission to deliver clinical tools that provide actionable information in the critical care settings, resulting in better care for patients and lower overall medical costs. The Quantra® Hemostasis Analyzer, the flagship product of HemoSonics, is designed to improve patient outcomes and reduce healthcare costs by providing unique and optimized coagulation information, for easy and fast interpretation and simple, more efficient point-of-care bleeding management workflows. HemoSonics is headquartered in Charlottesville, VA, with research, development and manufacturing facilities in Durham, NC. HemoSonics is part of the Stago group, a leading company in the in vitro diagnostics industry dedicated to the exploration of thrombosis and hemostasis. References: 1. US Food and Drug Administration. Coagulation Systems for Measurement of Viscoelastic Properties: Enforcement Policy During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency: Guidance for Industry and Food and Drug Administration Staff, January 2021. Available at: https://www.fda.gov/media/145135/download . 2. Centers for Disease Control and Prevention. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19). Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html . 3. Han H, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. 2020 Jun 25;58(7):1116-1120. doi: 10.1515/cclm-2020-0188. 4. Tang N, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18:844-47. 5. Darzi AJ, et al. Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis. Blood. 2020 May 14;135(20):1788-1810. doi: 10.1182/blood.2019003603. 6. Hunt B, et al. Practical guidance for the prevention of thrombosis and management of coagulopathy and disseminated intravascular coagulation of patients infected with COVID-19. https://thrombosisuk.org/covid-19-thrombosis.php . 7. Ranucci M, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost. 2020 Jul;18(7):1747-1751. doi: 10.1111/jth.14854. Contacts

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing HemoSonics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

HemoSonics is included in 1 Expert Collection, including Medical Devices.

M

Medical Devices

11,202 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

HemoSonics Patents

HemoSonics has filed 24 patents.

The 3 most popular patent topics include:

  • Coagulation system
  • Coagulopathies
  • Hematology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/31/2016

7/6/2021

Coagulation system, Hematology, Coagulopathies, Blood tests, Cardiac surgery

Grant

Application Date

5/31/2016

Grant Date

7/6/2021

Title

Related Topics

Coagulation system, Hematology, Coagulopathies, Blood tests, Cardiac surgery

Status

Grant

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.